Cargando…
Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity
Although current cancer immunotherapies that target PD-1/PD-L1 immune checkpoint to reinvigorate exhausted T cells have achieved impressive clinical outcomes, only a small proportion of patients respond. New therapeutic targets are therefore needed to be identified to further unleash the anti-tumor...
Autores principales: | Zheng, Shuang, Song, Jiaming, Linghu, Dongli, Yang, Riyao, Liu, Boning, Xue, Zhen, Chen, Qihui, Liu, Chengjie, Zhong, Diansheng, Hung, Mien-Chie, Sun, Linlin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909994/ https://www.ncbi.nlm.nih.gov/pubmed/36778120 http://dx.doi.org/10.7150/ijbs.79852 |
Ejemplares similares
-
Development and characterization of anti-galectin-9 antibodies that protect T cells from galectin-9-induced cell death
por: Yang, Riyao, et al.
Publicado: (2022) -
Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity
por: Sun, Xian, et al.
Publicado: (2023) -
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
por: Yang, Riyao, et al.
Publicado: (2021) -
Aldehyde dehydrogenase inhibitors promote DNA damage in ovarian cancer and synergize with ATM/ATR inhibitors
por: Grimley, Edward, et al.
Publicado: (2021) -
Activation of phagocytosis by immune checkpoint blockade
por: Li, Chia-Wei, et al.
Publicado: (2018)